Clovis slides on rociletinib data, keeps pace with AstraZeneca
This article was originally published in Scrip
Clovis Oncology saw its stock slide 10.2% on 19 November based on updated results from the Phase II portion of the ongoing TIGER-X Phase I/II clinical trial for its next generation epidermal growth factor receptor (EGFR) inhibitor rociletinib (CO-1686) in many lung cancer patients with a T790M mutation and some patients who don't have the treatment-resistant mutation.
You may also be interested in...
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.